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On December 3, 2014, the Pharmacology Risk SRP, participants from the JSC, HQ, the NSBRI, 
and NRESS participated in a WebEx/teleconference.  The purpose of the call (as stated in the 
Statement of Task) was to allow the SRP members to: 
 
1. Receive an update by the Human Research Program (HRP) Chief Scientist or Deputy 
Chief Scientist on the status of NASA’s current and future exploration plans and the 
impact these will have on the HRP. 
2. Receive an update on any changes within the HRP since the 2013 SRP meeting. 
3. Receive an update by the Element or Project Scientist(s) on progress since the 2013 SRP 
meeting. 
4. Participate in a discussion with the HRP Chief Scientist, Deputy Chief Scientist, and the 
Element regarding possible topics to be addressed at the next SRP meeting 
 
Based on the presentations and the discussion during the WebEx/teleconference, the SRP would 
like to relay the following information to Dr. Shelhamer, the HRP Chief Scientist. 
 
1. The SRP thinks that the pharmacology portfolio has made significant progress in the past 
year. 
 
2. The SRP is pleased that their previous comments about the in-flight medication use 
survey, dose tracker initiative, and pharmacology database tasks were acknowledged and 
are finally underway.  The SRP believes these tools will continue to be developed and 
can be a source of data for future and retrospective studies. 
 
3. The dose tracker is a very useful tool and has a lot of promise.  Depending on how well it 
performs, the SRP thinks it could be broadened to clinical trials, monitoring compliance, 
etc. 
 
4. While the ad-hoc stability study of in-flight medications may provide some useful data, 
the lack of ground-based samples is a major limitation.  The SRP strongly recommends 
that for any future medication stability studies, ground samples be collected and stored 
prospectively in order to provide conclusive and potentially actionable information. 
 
5. The SRP thinks there are several approaches to drug stability studies that can be 
performed.  The information obtained could be placed in a drug stability database.  In 
addition to the NASA space program, a drug stability database could be useful for 
various organizations such as the World Health Organization (WHO) and certain 
developing countries to know if a drug may be used safely after the expiration date.  The 
SRP would also suggest that a detailed database on drug stability might be useful for the 
U.S. Food and Drug Administration (FDA) to predict stability of drugs that are in the 
same chemical class but have not yet been approved for marketing. 
 
6. The real-time medication analyzer currently under development (Small Business 
Innovation Research grant: Low Gravity Drug Stability Analyzer (PI: Farquharson, Real 
Time Analyzers)) should be thoroughly validated, including comparison to the chemical 
analyzer results of ground and in-flight samples. 






7. The SRP recommends that the pharmacology discipline collaborate closely with other 
clinical disciplines on the need for additional assessments of QTc-prolongation liability 
for medications used in-flight. 
 
 
